"MILNACIPRAN" in Subjects With Chronic Shoulder Pain

An Exploratory, Randomized, Single Blinded, Placebo-Controlled, Dose-Ranging Study of the Safety and Efficacy of "MILNACIPRAN" in Subjects With Chronic Shoulder Pain

The purpose of this study is to compare the safety and efficacy of multiple doses of "Milnacipran" to a placebo dose in subjects with Chronic Shoulder Pain.

Study Overview

• Status: Completed
• Conditions: Chronic Shoulder Pain
• Intervention / Treatment: Drug: Placebo; Drug: Milnacipran; Drug: milnacipran

Detailed Description

16 weeks. It is planned that this study will be conducted at a single site and will enroll approximately 40 subjects over 2-4 months. At the end of the 12-week dosing period, the study drug will be discontinued and all subjects in the treatment groups and control group will be followed for an additional 4 weeks.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Florida
    • Delray Beach, Florida, United States, 33484
      • Delray Research Associates

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Males, postmenopausal/ sterile females or females using reliable contraceptives who are >25 years of age.
2. Chronic shoulder pain in at least one shoulder for > 3 months (If both shoulders are painful, the investigator will choose the most painful shoulder for evaluation during the study) If both are equally painful, the investigator will choose the shoulder for evaluation.
3. History of shoulder or proximal arm pain due to bursitis, osteoarthritis of the shoulder, impingement or rotator cuff tear.
4. Subjects who give their written informed consent.
5. Subjects who at screening are not on chronic analgesic/anti-inflammatory medication and have a VAS pain score of > 40mm and < 90mm or subjects who are on chronic analgesic/anti-inflammatory medication at screening and have a VAS pain score of > 30mm and < 90mm, indicating a lack of adequate and sustained response to current therapy.
6. At baseline, after all analgesic/anti-inflammatory medication has been discontinued for 2 weeks (including withdrawal from acetaminophen rescue medication for 24 hours prior to screening) should have a VAS pain score of > 40mm and < 90mm.
7. Subjects who are willing to discontinue all NSAIDs or other analgesic medication taken for their shoulder pain with the exception of acetaminophen 500-1000mg (1-2 tablets) q.i.d., p.r.n. (maximum 8 tablets or 4 grams per day. Subjects must be willing to use only acetaminophen as a rescue pain medication for the shoulder pain. All analgesic medications must be stopped at least 2 weeks prior to the baseline visit and all acetaminophen must be discontinued at least 24 hours prior to the baseline visit. Subjects must be willing to abstain from any peri-articular injections for the shoulder during the course of the trial.
8. Subjects who have an x-ray at screening or MRI within 6 months prior to screening.

Exclusion Criteria:

1. Women of childbearing potential may not be entered if:

   Their pregnancy tests (urine) are positive They are nursing They do not use or agree to use an effective method of contraception until all follow-up procedures are complete. (Acceptable methods of contraception are oral, injectable, implanted contraceptive agent, abstinence or an intra-uterine device with a failure rate of < 1%

2. Participation in another experimental drug/device study within the past 30 days.
3. Acute infection of the study joint
4. History of adverse reaction or allergy to milnacipran or acetaminophen
5. Shoulder pain due to an injury for which litigation is planned or pending.
6. Any cervical spine disease that in the opinion of the investigator could confound assessments during the study.
7. Use of any oral corticosteroid during the past 30 days or peri-articular corticosteroid injection during the past 1 month.
8. Subjects with shoulder x-ray findings of fractures or avascular necrosis.
9. Subjects with any inter-current disease or condition that may interfere with the free use or evaluation of the affected shoulder for the duration of their participation in the study (severe congenital defects, weight bearing use of the shoulder due to crutches, walkers, canes etc.)
10. Subjects with history of alcohol or drug abuse within the past 5 years.
11. Subjects who have a compromised mental capacity or who may be unable to legally comprehend the details and nature of the study.
12. In the opinion of the investigator, a clinically significant abnormal lab results or history of disease that may place the subject at a health risk or compromise the study data or affect the subject's ability to complete the study.
13. Subjects who in the opinion of the investigator are unlikely to adhere to the study protocol or to complete the study as planned.
14. Subject has a chronic pain condition (chronic low back pain, chronic headache, fibromyalgia, chronic osteoarthritis, chronic rheumatoid arthritis etc.) that could confound the shoulder pain response to the study medication(in the opinion of the investigator)
15. Subject is using and is not willing to discontinue opioids, topical counterirritants (eg methylsalicylate or capsaicin) or the use of orthopedic devices for the study shoulder.
16. Significant liver impairment (defined as liver enzymes elevated more than three times the upper limit of normal) or significant renal impairment (defined as a serum creatinine level greater than twice the upper limit of normal.
17. Uncontrolled hypertension, history of stroke or transient ischemic attack within 6 months of enrollment, epilepsy, history of malignant neoplastic disease that is active (basal cell carcinoma of the skin is permitted), active infectious disease.
18. Subjects who have a history of uncontrolled Narrow Angle Glaucoma
19. Subjects who test positive for illegal or prohibited substances at Screening as demonstrated by a positive urine test or based on the Investigator's judgment.
20. Subjects who have active peptic ulcer disease, a history of inflammatory bowel disease or celiac sprue.
21. Subjects who have pulmonary dysfunction or severe chronic obstructive pulmonary disease that in the Investigator's opinion could interfere with study participation and completion.
22. Subjects who have unstable endocrine disease, including unstable diabetes or thyroid disease. Subjects with endocrine disorders that have been stable for the preceding 3 months will be permitted to enroll.
23. Male subjects with prostatic enlargement or other genitourinary disorders that put them at potentially significant risk for dysuria and/or urinary retention while taking agents with noradrenaline-reuptake inhibition properties (Entry permitted at Investigator's discretion)
24. Subjects who must participate in Physical Therapy during the course of their participation, unless stable in the opinion of the investigator.
25. Subjects with shoulder pain or other referred pain that does not originate from the shoulder.
26. Subjects who are taking SNRIs such as: Cymbalta
27. Subjects who are taking Lyrica or Neurontin
28. Subjects with cervical radiculopathy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: SINGLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Placebo; Placebo BID (twice daily, approximately 12 hours apart)	Drug: Placebo; 1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
ACTIVE_COMPARATOR: milnacipran 200 mg; 200mg- 1 100mg tablet BID (twice daily, approximately 12 hours apart)	Drug: Milnacipran; 1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.; Other Names: Savella
ACTIVE_COMPARATOR: milnacipran 100 mg; 100mg- 1 50mg tablet BID (twice daily, approximately 12 hours apart)	Drug: milnacipran; 1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period; Other Names: Savella

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The primary efficacy endpoint will be the reduction in the mean VAS for chronic shoulder pain	The primary efficacy endpoint will be the reduction in the mean VAS (Visual Analog Scale) for chronic shoulder pain at Week 12	Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvement in the PGIC	Overall improvement in the PGIC (Patient Global Impression of Change) at Week 12	Week 12
An improvement in the SPADI score	Improvement in the SPADI (Shoulder Pain and Disability Index) score at Week 12	Week 12
Improvement in the SF-36 Health Questionnaire	Improvement in the SF-36 (Short Form-36) Health Questionnaire at Week 12	Week 12

Collaborators and Investigators

• Sponsor: Valera Bussell
• Collaborators: Forest Laboratories
• Investigators: Principal Investigator: Philippe A Saxe, MD,FACP, Delray Research Associates

Study record dates

Study Major Dates

• Study Start: October 1, 2009
• Primary Completion (ACTUAL): June 1, 2011
• Study Completion (ACTUAL): June 1, 2011

Study Registration Dates

• First Submitted: February 1, 2011
• First Submitted That Met QC Criteria: February 2, 2011
• First Posted (ESTIMATE): February 3, 2011

Study Record Updates

• Last Update Posted (ESTIMATE): August 9, 2012
• Last Update Submitted That Met QC Criteria: August 7, 2012
• Last Verified: August 1, 2012

More Information

Terms related to this study

• Keywords: Shoulder Pain
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Joint Diseases; Musculoskeletal Diseases; Arthralgia; Shoulder Pain; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Psychotropic Drugs; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Antidepressive Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Milnacipran; Levomilnacipran
• Other Study ID Numbers: SAV-MD-02